CV Therapeutics Nasdaq CVTX

Related by string. * CVs . CVD . cv : cardiovascular disease CVD . CVS pharmacy LPGA . SAB de CV / THERAPEUTICS . THERAPEUTIC . therapeutics : small molecule therapeutics . Therapeutic Competitors include . Qualifying Therapeutic Discovery / NASDAQ. . nasdaq . NASDAQ : Inc. NASDAQ SCOR . NASDAQ OMX Group . Nasdaq Listing Qualifications / : CV Therapeutics CVTX . CVTX . Inc. Nasdaq CVTX * *

Related by context. Frequent words. (Click for all words.) 58 Biogen Idec BIIB 57 Immunogen 57 Gilead Sciences GILD 56 Afrezza 55 AstraZeneca AZN 55 Auxilium Pharmaceuticals 55 HGSI 55 Indiplon 55 ONXX 55 Genzyme GENZ 55 Orexigen Therapeutics 55 Avanir Pharmaceuticals 55 OSIP 54 VRTX 54 Avanir 54 Bristol Myers Squibb BMY 54 Bydureon 54 AMLN 54 Schering Plough SGP 53 Savient Pharmaceuticals 53 Pfizer PFE 53 phase IIa 53 Novartis NVS 53 Amgen AMGN 53 Phase III trials 53 Eli Lilly NYSE LLY 53 Amgen Nasdaq AMGN 53 VVUS 53 Sanofi Aventis NYSE SNY 53 tanezumab 53 Vertex Pharmaceuticals 53 KERX 52 phase IIb 52 SPPI 52 taspoglutide 52 Novartis NYSE NVS 52 nebivolol 52 Eli Lilly LLY 52 HuMax CD# 52 Onyx Pharmaceuticals 52 Ranexa 52 Encysive Pharmaceuticals 52 daclizumab 51 MNKD 51 AMAG Pharmaceuticals 51 GVAX 51 Halozyme Therapeutics 51 BioMS 51 Encysive 51 BIIB 51 motavizumab 51 Cordaptive 51 Exanta 51 Momenta Pharmaceuticals 50 Replagal 50 Pfizer NYSE PFE 50 Amgen NASDAQ AMGN 50 Regeneron Pharmaceuticals Inc. 50 Cimzia 50 EXEL 50 alogliptin 50 cladribine 50 Gilenia 50 MYGN 50 SVNT 50 bapineuzumab 50 Corcept 50 bifeprunox 50 Osiris Therapeutics 50 Phase IIa trial 49 Sirtris Pharmaceuticals 49 Trexima 49 Board DSMB 49 exenatide LAR 49 Halozyme Therapeutics Inc. 49 Myogen 49 Flutiform 49 febuxostat 49 darusentan 49 Antegren 49 OREX 49 Phase IIa clinical 49 Xarelto 49 PDLI 49 Rivaroxaban 49 Qnexa 48 Biogen Idec NASDAQ BIIB 48 DNDN 48 Immunomedics 48 BMRN 48 Liraglutide 48 multicenter clinical 48 clinical trial 48 ISTA Pharmaceuticals 48 asenapine 48 SLXP 48 Saphris 48 clinical trials 48 Delcath Systems 48 Cypress Bioscience 48 midstage study

Back to home page